KR100645448B1 - 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법 - Google Patents

세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법 Download PDF

Info

Publication number
KR100645448B1
KR100645448B1 KR1019997004445A KR19997004445A KR100645448B1 KR 100645448 B1 KR100645448 B1 KR 100645448B1 KR 1019997004445 A KR1019997004445 A KR 1019997004445A KR 19997004445 A KR19997004445 A KR 19997004445A KR 100645448 B1 KR100645448 B1 KR 100645448B1
Authority
KR
South Korea
Prior art keywords
sulfabin
delete delete
nucleic acid
acid molecule
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019997004445A
Other languages
English (en)
Korean (ko)
Other versions
KR20000057159A (ko
Inventor
다리오씨. 알티에르
Original Assignee
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 예일 유니버시티 filed Critical 예일 유니버시티
Publication of KR20000057159A publication Critical patent/KR20000057159A/ko
Application granted granted Critical
Publication of KR100645448B1 publication Critical patent/KR100645448B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
KR1019997004445A 1996-11-20 1997-11-20 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법 Expired - Lifetime KR100645448B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3143596P 1996-11-20 1996-11-20
US60/031,435 1996-11-20
US08/975,080 US6245523B1 (en) 1996-11-20 1997-11-20 Survivin, a protein that inhibits cellular apoptosis, and its modulation
US8/975,080 1997-11-20
US08/975,080 1997-11-20

Publications (2)

Publication Number Publication Date
KR20000057159A KR20000057159A (ko) 2000-09-15
KR100645448B1 true KR100645448B1 (ko) 2006-11-13

Family

ID=26707241

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997004445A Expired - Lifetime KR100645448B1 (ko) 1996-11-20 1997-11-20 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법

Country Status (10)

Country Link
US (7) US6245523B1 (https=)
EP (1) EP0950103B1 (https=)
JP (2) JP4672092B2 (https=)
KR (1) KR100645448B1 (https=)
AT (1) ATE414149T1 (https=)
AU (1) AU736587B2 (https=)
CA (1) CA2271783C (https=)
DE (1) DE69739105D1 (https=)
IL (1) IL130036A (https=)
WO (1) WO1998022589A2 (https=)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6245523B1 (en) * 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
US20030033621A1 (en) * 1997-02-26 2003-02-13 De La Monte Suzanne Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
CA2282729A1 (en) * 1997-02-26 1998-09-03 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
US7226730B1 (en) * 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
EP1066527A2 (en) * 1998-04-01 2001-01-10 Yale University Method to identify modulators of survivin - tubulin interaction
WO2000003693A1 (en) * 1998-07-14 2000-01-27 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
AU2003205017B2 (en) * 1998-09-29 2005-12-15 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
EP1237582B1 (en) 1999-12-10 2011-09-14 AntiCancer, Inc. Methods for introducing genes into mammalian subjects
US6509162B1 (en) 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways
AU2001273102A1 (en) * 2000-06-29 2002-01-14 The Salk Institute For Biological Studies Crystal structure of survivin
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
US7097966B2 (en) 2001-01-12 2006-08-29 Yale University Detection of survivin in the biological fluids of cancer patients
DE10102722A1 (de) * 2001-01-22 2002-08-14 Medinnova Ges Med Innovationen Verfahren und Testsystem zum Auffinden von Nervenzell-schützenden Substanzen
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040102395A1 (en) * 2002-11-22 2004-05-27 Isis Pharmaceuticals Inc. Modulation of IAP-like expression
AU2003295598B2 (en) 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
WO2004058293A1 (en) * 2002-12-24 2004-07-15 Northern Therapeutics Inc. Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2633389T3 (es) 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
CA2515096A1 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
DE602004027902D1 (de) * 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
BRPI0410886A (pt) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
WO2005049073A2 (en) 2003-11-19 2005-06-02 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
CA2551267C (en) * 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1756308A1 (en) * 2004-04-23 2007-02-28 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
ES2671893T3 (es) 2004-10-06 2018-06-11 Mayo Foundation For Medical Education And Research B7-H1 y PD-1 en el tratamiento del carcinoma de células renales
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
EP1815014B1 (en) * 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
KR20070095882A (ko) 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 Ｌｎａ 올리고뉴클레오티드 및 암의 치료
WO2006051075A1 (en) 2004-11-12 2006-05-18 Vib Vzw Use of survivin to treat kidney failure
US20060135461A1 (en) * 2004-12-22 2006-06-22 Natalia Botchkareva Reduction of hair growth
CN103143004A (zh) 2005-02-04 2013-06-12 萨瓦克公司 存活蛋白肽疫苗
US7803375B2 (en) * 2005-02-23 2010-09-28 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20060276423A1 (en) * 2005-04-18 2006-12-07 Rachel Altura Survivin-directed RNA interference-compositions and methods
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US7272013B1 (en) * 2005-07-28 2007-09-18 American Megatrends, Inc. Interchangeable design support system
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US7812173B2 (en) * 2005-08-23 2010-10-12 E.I. Du Pont De Nemours And Company Tetrahydro-1,8-dioxa-4a-aza-naphthalenes in coating applications
US20070049752A1 (en) * 2005-08-23 2007-03-01 Drysdale Neville E Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007082144A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
AU2007353412A1 (en) * 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US8974526B2 (en) * 2007-08-27 2015-03-10 Amo Groningen B.V. Multizonal lens with extended depth of focus
US9216080B2 (en) 2007-08-27 2015-12-22 Amo Groningen B.V. Toric lens with decreased sensitivity to cylinder power and rotation and method of using the same
US8466140B2 (en) * 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
ATE523810T1 (de) 2008-02-15 2011-09-15 Amo Regional Holdings System, brillenglas und verfahren zur erweiterung der fokustiefe
US8439498B2 (en) 2008-02-21 2013-05-14 Abbott Medical Optics Inc. Toric intraocular lens with modified power characteristics
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
AU2009228146B2 (en) 2008-03-28 2015-06-04 Johnson & Johnson Surgical Vision, Inc. Systems for ocular measurements
CN101981187A (zh) * 2008-03-31 2011-02-23 株式会社生物免疫平衡 MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法
US8862447B2 (en) 2010-04-30 2014-10-14 Amo Groningen B.V. Apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses
EP3824846B1 (en) 2009-12-18 2024-10-30 AMO Groningen B.V. Limited echelette lens
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
US9817246B2 (en) 2010-12-01 2017-11-14 Amo Groningen B.V. Multifocal lens having an optical add power progression, and a system and method of providing same
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
US9717628B2 (en) 2012-12-04 2017-08-01 Amo Groningen B.V. Lenses, systems and methods for providing binocular customized treatments to correct presbyopia
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US10022441B2 (en) 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
US20160279213A1 (en) * 2013-12-16 2016-09-29 Merck Patent Gmbh Survivin-Directed Cancer Vaccine Therapy
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (en) 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
WO2016179573A1 (en) * 2015-05-07 2016-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Variant survivin vaccine for treatment of cancer
ES2883128T3 (es) 2015-09-04 2021-12-07 Health Research Inc Anticuerpos anti-survivina para la terapia contra el cáncer
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
EP3377099A4 (en) 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
CA3013858A1 (en) 2016-02-09 2017-08-17 Amo Groningen B.V. Progressive power intraocular lens, and methods of use and manufacture
AU2017237076B2 (en) 2016-03-23 2021-11-18 Johnson & Johnson Surgical Vision, Inc. Ophthalmic apparatus with corrective meridians having extended tolerance band with freeform refractive surfaces
EP3932368B1 (en) 2016-03-23 2025-02-26 Johnson & Johnson Surgical Vision, Inc. Ophthalmic apparatus with corrective meridians having extended tolerance band
US11060087B2 (en) * 2016-06-15 2021-07-13 The Regents Of The University Of California Synthetic promoters for high throughput screening and gene modulation
EP3522771B1 (en) 2016-10-25 2022-04-06 Amo Groningen B.V. Realistic eye models to design and evaluate intraocular lenses for a large field of view
US10739227B2 (en) 2017-03-23 2020-08-11 Johnson & Johnson Surgical Vision, Inc. Methods and systems for measuring image quality
AU2018376564B2 (en) 2017-11-30 2024-11-14 Amo Groningen B.V. Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US11886046B2 (en) 2019-12-30 2024-01-30 Amo Groningen B.V. Multi-region refractive lenses for vision treatment
WO2022233683A1 (en) 2021-05-05 2022-11-10 Amo Groningen B.V. Ring halometer system and method for quantifying dysphotopsias
AU2022403148A1 (en) 2021-12-03 2024-07-18 Amo Groningen B.V. Lenses having multi-ring design for vision treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6238875B1 (en) 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
US6070969A (en) * 1994-03-23 2000-06-06 Hewlett-Packard Company Thermal inkjet printhead having a preferred nucleation site
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US6245523B1 (en) * 1996-11-20 2001-06-12 Yale University Survivin, a protein that inhibits cellular apoptosis, and its modulation
EP1066527A2 (en) * 1998-04-01 2001-01-10 Yale University Method to identify modulators of survivin - tubulin interaction
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US6509162B1 (en) * 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
US7097966B2 (en) * 2001-01-12 2006-08-29 Yale University Detection of survivin in the biological fluids of cancer patients
US6949558B2 (en) * 2001-11-07 2005-09-27 Yale University Enhancement of taxane-based chemotherapy by a CDK1 antagonist
CA2509825A1 (en) * 2002-12-13 2004-07-01 The Ohio State University Antagonists for human prolactin
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins

Also Published As

Publication number Publication date
WO1998022589A2 (en) 1998-05-28
EP0950103B1 (en) 2008-11-12
CA2271783A1 (en) 1998-05-28
WO1998022589A3 (en) 1998-10-29
EP0950103A2 (en) 1999-10-20
HK1027112A1 (en) 2001-01-05
IL130036A (en) 2010-04-15
AU736587B2 (en) 2001-08-02
KR20000057159A (ko) 2000-09-15
US20060068453A1 (en) 2006-03-30
US6943150B1 (en) 2005-09-13
ATE414149T1 (de) 2008-11-15
IL130036A0 (en) 2000-02-29
CA2271783C (en) 2013-04-16
US20030100525A1 (en) 2003-05-29
JP2009073860A (ja) 2009-04-09
US20110136743A1 (en) 2011-06-09
JP2002514060A (ja) 2002-05-14
US20060069025A1 (en) 2006-03-30
AU7301898A (en) 1998-06-10
JP4672092B2 (ja) 2011-04-20
DE69739105D1 (de) 2008-12-24
US20050143308A1 (en) 2005-06-30
US6800737B2 (en) 2004-10-05
US6245523B1 (en) 2001-06-12

Similar Documents

Publication Publication Date Title
KR100645448B1 (ko) 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
WO1998022589A9 (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
DE69824287T2 (de) Prostata stammzell-antigen (psca)
Gutierrez et al. The Fas/Fas‐ligand system: a mechanism for immune evasion in human breast carcinomas
ES2298896T3 (es) Composiciones y procedimientos para el tratamiento de tumores.
US20050037439A1 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US8946390B2 (en) Cancer-associated antigen
JPH11511013A (ja) 哺乳類アポトーシス抑制性蛋白質遺伝子ファミリー、プライマー、プローブおよび検出法
JP2002512602A (ja) 増殖性疾患の診断および治療のためのｉａｐ類およびｎａｉｐの検出および調節
US20020173461A1 (en) Methods for enhancing the efficacy of cancer therapy
KR20050103474A (ko) 갈렉틴 9 함유 의약
EP1666600B1 (en) Methods for enhancing the efficacy of cancer therapy
US6171857B1 (en) Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity
CA2379345A1 (en) T-cell receptor .gamma. alternate reading frame protein, (tarp) and uses thereof
KR100865801B1 (ko) 암 치료의 효능을 증진시키는 방법
KR100448426B1 (ko) 신생 세포 성장을 억제하기 위한 방법 및 조성물
HK1027112B (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
CA2447958A1 (en) Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
MXPA99004677A (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
JP2003000271A (ja) 新規ポリぺプチド、新規ｄｎａ、新規抗体および新規遺伝子改変動物
US20060057153A1 (en) Method and composition for the inhibition of mitosis
AU2003200204C1 (en) Novel PRO792 polypeptides and nucleic acids encoding same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990520

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021120

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20041130

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050504

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20060224

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20050504

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20041130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20060529

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20060224

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20060808

Appeal identifier: 2006101004557

Request date: 20060529

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20060628

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20060529

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20060203

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20050228

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20021120

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20060808

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20060718

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20061106

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20061107

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100205

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101027

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20111026

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20121023

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20121023

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20131023

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20131023

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20141023

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20141023

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20151023

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20151023

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20161024

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20161024

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20171023

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20171023

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20180520

Termination category: Expiration of duration